ClinicalTrials.gg
CompletedNCT00739999Updated Mar 15, 2021Results posted

8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia

A Phase 1 interventional study of Atorvastatin and Atorvastatin in Pediatric Heterozygous Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 3 sites in 3 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-03-15.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
64th of 75
39 · median 148
Started
2008
with 12 others
Phase 1
4 of 77
none open now
Registered
30th of 77
by date
Lead sponsor
10 of 77
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 64th largest by enrollment of the 75 interventional ones that give a count, is one of 13 that started in 2008, is one of 4 in phase 1, and was the 30th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

To evaluate pharmacokinetics, pharmacodynamics, safety and tolerability of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia

03

Conditions studied

  • Pediatric Heterozygous Hypercholesterolemia

Keywords

  • heterozygous familial hypercholesterolemia (HeFH); atorvastatin; pediatric
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genetically confirmed heterozygous familial hypercholesterolemia (HeFH) with LDL greater or equal 4 mmol/L at baseline

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of diseases, homozygous familial hypercholesterolemia (FH)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Other
    1

    6-10 years will be administered with atorvastatin tablet formulation with initial doses based on age cohort.

    Drug: Atorvastatin

  • Other
    2

    10-17 years will be administered 10-mg daily dose of atorvastatin tablet formulation.

    Drug: Atorvastatin

Interventions

  • 6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.

  • 10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.

06

What researchers measure

Primary outcomes

  1. Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F)

    Parent-metabolite population PK model built using sparse blood samples from both Tanner Stage 1 and Tanner Stage 2+. Blood sampling times: Weeks 2 and 6: single sample between 4 and 12 hours postdose; Weeks 4 and 8: predose, 1 hour, and 2 hours postdose. Plasma samples were analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using a validated, sensitive, and specific high-performance liquid chromatography tandem mass spectrometric method. Data presented are the result of the model used.

    Time frame: Week 2, Week 4, Week 6, Week 8

  2. Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Apparent Volume of Distribution of the Central Compartment (Vc/F)

    Parent-metabolite population PK model built using sparse blood samples from Tanner Stages 1 and 2+. Sampling times: Weeks 2 + 6: single sample between 4 -12 hours postdose; Weeks 4 + 8: predose, 1 + 2 hours postdose. Plasma samples analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using validated, sensitive, specific high-performance liquid chromatography tandem mass spectrometric method. Vc/F value based on 70 kg body weight. Parameter estimation uncertainty (95% CI) by non-parametric bootstrap analysis. Data presented are result of model used.

    Time frame: Week 2, Week 4, Week 6, Week 8

Secondary outcomes

  1. Absolute Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)

    Low-density lipoprotein cholesterol (LDL-C) measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  2. Percent Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)

    Low-density Lipoprotein Cholesterol (LDL-C): percent (%) change from baseline by treatment over time = \[LDL-C at observation minus LDL-C at Week 0\] divided by LDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  3. Absolute Change From Baseline in Total Cholesterol (TC)

    Total Cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  4. Percent Change From Baseline in Total Cholesterol (TC)

    Total cholesterol (TC): percent (%) change from baseline by treatment over time = \[TC at observation minus TC at Week 0\] divided by TC at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  5. Absolute Change From Baseline in Triglycerides (TG)

    Change from baseline in triglycerides measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  6. Percent Change From Baseline in Triglycerides (TG)

    Triglycerides (TG): percent (%) change from baseline by treatment over time = \[TG at observation minus TG at Week 0\] divided by TG at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  7. Absolute Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)

    Change from baseline in high-density lipoprotein cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  8. Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)

    High-density lipoprotein cholesterol (HDL-C): percent (%) change by treatment over time = \[HDL-C at observation minus HDL-C at Week 0\] divided by HDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  9. Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1)

    Change from baseline in Apolipoprotein A-1 measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  10. Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1)

    Apolipoprotein A-1 (Apo A-1): percent (%) change from baseline by treatment over time = \[Apo A-1 at observation minus Apo A-1 at Week 0\] divided by Apo A-1 at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  11. Absolute Change From Baseline in Apolipoprotein B (Apo B)

    Change from baseline in Apolipoprotein B measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  12. Percent Change From Baseline in Apolipoprotein B (Apo B)

    Apolipoprotein B (Apo B): percent (%) change from baseline by treatment over time = \[Apo B at observation minus Apo B at Week 0\] divided by Apo B at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  13. Absolute Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)

    Change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) measured in millimoles per liter (mmol/L). Change from baseline = value at observation minus baseline value. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  14. Percent Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)

    Very low-density lipoprotein-cholesterol (VLDL-C): percent (%) change from baseline by treatment over time = \[VLDL-C at observation minus VLDL-C at Week 0\] divided by VLDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8

  15. Absolute Change From Baseline in Flow-Mediated Dilatation at Week 8

    Brachial artery flow-mediated dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. Standardized image acquisition: brachial artery images recorded for one minute at rest, blood pressure cuff inflated to 250 mm Hg for 5 minutes with brachial artery imaged continuously throughout cuff inflation, cuff released to produce reactive hyperaemia and the brachial artery imaged continuously for 3 minutes after release. Total duration of measurement approximately 25 minutes. Change from baseline = value at observation minus baseline value.

    Time frame: Baseline, Week 8

  16. Percent Change From Baseline in Flow-Mediated Dilatation at Week 8

    Brachial Flow-Mediated Dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. .

    Time frame: Baseline, Week 8

07

Results

Posted Aug 20, 2010

Participant flow

Subjects were enrolled at 3 medical centers and participated in the study between 02 December 2008 and 13 May 2009.

Participant flow — Overall Study
MilestoneAtorvastatin (5 mg, 10 mg): Tanner Stage 1Atorvastatin (10 mg, 20 mg): Tanner Stage 2+
Started1524
Completed1524
Not completed00

Outcome measures

PrimaryParent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F)

Parent-metabolite population PK model built using sparse blood samples from both Tanner Stage 1 and Tanner Stage 2+. Blood sampling times: Weeks 2 and 6: single sample between 4 and 12 hours postdose; Weeks 4 and 8: predose, 1 hour, and 2 hours postdose. Plasma samples were analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using a validated, sensitive, and specific high-performance liquid chromatography tandem mass spectrometric method. Data presented are the result of the model used.

Time frame:
Week 2, Week 4, Week 6, Week 8
Reported as:
Number · L/hr
Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F)
L/hrAtorvastatin (5 mg, 10 mg): Tanner Stage 1Atorvastatin (10 mg, 20 mg): Tanner Stage 2+
Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F)553543
Statistical analysis
  • Atorvastatin (5 mg, 10 mg): Tanner Stage 1 vs Atorvastatin (10 mg, 20 mg): Tanner Stage 2+ · non-linear mixed-effects model · Atorvastatin cl/f based on 70 kg bw: 699 · 95% CI 570 to 881Measures of parameter estimation uncertainty (95% CI) were determined by non-parametric bootstrap analysis.
SecondaryAbsolute Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)

Low-density lipoprotein cholesterol (LDL-C) measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · mmol/L
Absolute Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)
mmol/LStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Baseline4.87 ± 0.486.37 ± 1.105.11 ± 0.656.23 ± 1.00
Week 2-1.75 ± 0.72-1.62 ± 0.46-1.95 ± 0.52-1.90 ± 0.72
Week 4-2.07 ± 0.50-1.94 ± 0.56-2.24 ± 0.57-2.27 ± 1.04
Week 6-1.89 ± 0.42-2.57 ± 0.70-2.12 ± 0.74-2.55 ± 1.02
Week 8-1.80 ± 0.63-2.71 ± 0.60-1.99 ± 0.58-2.60 ± 1.01
SecondaryPercent Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)

Low-density Lipoprotein Cholesterol (LDL-C): percent (%) change from baseline by treatment over time = \[LDL-C at observation minus LDL-C at Week 0\] divided by LDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · percent change in LDL-C
Percent Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)
percent change in LDL-CStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Week 2-36.27 ± 14.72-25.70 ± 7.76-38.14 ± 9.35-30.27 ± 9.22
Week 4-42.33 ± 8.24-30.27 ± 5.72-43.66 ± 7.78-35.13 ± 12.01
Week 6-38.87 ± 7.84-40.01 ± 6.34-41.22 ± 11.34-39.73 ± 10.40
Week 8-36.78 ± 11.16-42.70 ± 6.45-38.45 ± 7.84-40.39 ± 11.71
SecondaryAbsolute Change From Baseline in Total Cholesterol (TC)

Total Cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · mmol/L
Absolute Change From Baseline in Total Cholesterol (TC)
mmol/LStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Baseline6.76 ± 0.468.58 ± 1.066.92 ± 0.718.40 ± 1.10
Week 2-1.89 ± 0.79-2.04 ± 0.69-2.11 ± 0.53-2.28 ± 0.82
Week 4-2.27 ± 0.63-2.24 ± 0.49-2.37 ± 0.61-2.66 ± 1.29
Week 6-2.03 ± 0.53-2.86 ± 0.79-2.28 ± 0.73-2.95 ± 1.19
Week 8-1.89 ± 0.44-3.20 ± 0.65-2.26 ± 0.69-3.22 ± 1.14
SecondaryPercent Change From Baseline in Total Cholesterol (TC)

Total cholesterol (TC): percent (%) change from baseline by treatment over time = \[TC at observation minus TC at Week 0\] divided by TC at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · percent change in TC
Percent Change From Baseline in Total Cholesterol (TC)
percent change in TCStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Week 2-28.06 ± 11.23-24.11 ± 8.97-30.60 ± 7.49-26.78 ± 7.59
Week 4-33.37 ± 7.81-26.12 ± 4.24-33.98 ± 7.13-30.54 ± 11.60
Week 6-29.99 ± 8.00-33.12 ± 6.83-32.80 ± 8.97-34.06 ± 9.94
Week 8-27.80 ± 5.56-37.17 ± 5.28-32.43 ± 8.53-37.45 ± 9.89
SecondaryAbsolute Change From Baseline in Triglycerides (TG)

Change from baseline in triglycerides measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · mmol/L
Absolute Change From Baseline in Triglycerides (TG)
mmol/LStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Baseline0.76 ± 0.150.95 ± 0.271.03 ± 0.371.20 ± 0.50
Week 20.05 ± 0.34-0.08 ± 0.280.05 ± 0.680.00 ± 0.47
Week 4-0.05 ± 0.29-0.26 ± 0.30-0.10 ± 0.51-0.10 ± 0.37
Week 60.40 ± 0.62-0.04 ± 0.24-0.12 ± 0.42-0.04 ± 0.32
Week 80.02 ± 0.28-0.16 ± 0.37-0.31 ± 0.43-0.28 ± 0.41
SecondaryPercent Change From Baseline in Triglycerides (TG)

Triglycerides (TG): percent (%) change from baseline by treatment over time = \[TG at observation minus TG at Week 0\] divided by TG at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · percent change in TG
Percent Change From Baseline in Triglycerides (TG)
percent change in TGStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Week 25.66 ± 38.26-6.87 ± 29.0828.37 ± 85.32-0.56 ± 32.19
Week 4-6.20 ± 32.55-21.43 ± 30.421.27 ± 50.81-7.60 ± 25.75
Week 657.06 ± 78.73-1.27 ± 23.91-4.43 ± 32.52-2.72 ± 24.80
Week 81.69 ± 31.48-9.88 ± 33.31-20.94 ± 39.24-21.11 ± 23.85
SecondaryAbsolute Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)

Change from baseline in high-density lipoprotein cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · mmol/L
Absolute Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)
mmol/LStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Baseline1.35 ± 0.121.45 ± 0.291.17 ± 0.181.18 ± 0.23
Week 20.08 ± 0.24-0.10 ± 0.29-0.05 ± 0.26-0.01 ± 0.20
Week 4-0.02 ± 0.050.00 ± 0.190.02 ± 0.21-0.01 ± 0.28
Week 6-0.12 ± 0.29-0.01 ± 0.180.04 ± 0.14-0.03 ± 0.23
Week 80.04 ± 0.22-0.07 ± 0.210.08 ± 0.25-0.08 ± 0.22
SecondaryPercent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)

High-density lipoprotein cholesterol (HDL-C): percent (%) change by treatment over time = \[HDL-C at observation minus HDL-C at Week 0\] divided by HDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · percent change in HDL-C
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)
percent change in HDL-CStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Week 25.38 ± 17.32-6.45 ± 21.01-4.11 ± 19.96-0.77 ± 17.66
Week 4-1.99 ± 3.901.59 ± 13.181.04 ± 17.381.77 ± 23.22
Week 6-10.18 ± 22.70-0.64 ± 10.353.28 ± 11.63-2.78 ± 21.49
Week 82.50 ± 15.02-2.84 ± 14.495.99 ± 21.02-5.19 ± 17.76
SecondaryAbsolute Change From Baseline in Apolipoprotein A-1 (Apo A-1)

Change from baseline in Apolipoprotein A-1 measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · g/L
Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1)
g/LStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Baseline1.42 ± 0.201.45 ± 0.201.29 ± 0.201.24 ± 0.15
Week 20.01 ± 0.17-0.08 ± 0.23-0.09 ± 0.22-0.01 ± 0.15
Week 4-0.09 ± 0.14-0.06 ± 0.13-0.06 ± 0.210.07 ± 0.29
Week 6-0.14 ± 0.18-0.02 ± 0.11-0.07 ± 0.19-0.04 ± 0.23
Week 8-0.03 ± 0.12-0.05 ± 0.13-0.04 ± 0.24-0.07 ± 0.21
SecondaryPercent Change From Baseline in Apolipoprotein A-1 (Apo A-1)

Apolipoprotein A-1 (Apo A-1): percent (%) change from baseline by treatment over time = \[Apo A-1 at observation minus Apo A-1 at Week 0\] divided by Apo A-1 at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · percent change in Apo A-1
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1)
percent change in Apo A-1Stayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Week 21.69 ± 11.21-5.24 ± 15.86-5.96 ± 16.76-0.53 ± 11.90
Week 4-5.15 ± 8.20-3.30 ± 8.11-3.73 ± 16.437.54 ± 25.24
Week 6-9.90 ± 14.01-0.97 ± 7.04-4.21 ± 14.81-2.82 ± 18.20
Week 8-1.24 ± 8.49-3.37 ± 9.35-2.60 ± 20.22-4.82 ± 16.13
SecondaryAbsolute Change From Baseline in Apolipoprotein B (Apo B)

Change from baseline in Apolipoprotein B measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]). Change from baseline = value at observation minus baseline value.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · g/L
Absolute Change From Baseline in Apolipoprotein B (Apo B)
g/LStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Baseline1.09 ± 0.131.49 ± 0.241.26 ± 0.141.52 ± 0.18
Week 2-0.23 ± 0.13-0.31 ± 0.19-0.39 ± 0.14-0.42 ± 0.16
Week 4-0.33 ± 0.11-0.40 ± 0.13-0.44 ± 0.10-0.47 ± 0.22
Week 6-0.27 ± 0.15-0.53 ± 0.17-0.42 ± 0.15-0.52 ± 0.18
Week 8-0.30 ± 0.08-0.59 ± 0.15-0.41 ± 0.17-0.49 ± 0.30
SecondaryPercent Change From Baseline in Apolipoprotein B (Apo B)

Apolipoprotein B (Apo B): percent (%) change from baseline by treatment over time = \[Apo B at observation minus Apo B at Week 0\] divided by Apo B at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · percent change in Apo B
Percent Change From Baseline in Apolipoprotein B (Apo B)
percent change in Apo BStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Week 2-21.92 ± 13.97-19.88 ± 10.96-30.81 ± 10.27-27.46 ± 8.89
Week 4-29.89 ± 8.94-26.56 ± 5.33-34.69 ± 6.10-30.42 ± 11.86
Week 6-24.58 ± 12.96-35.26 ± 6.85-33.26 ± 10.38-33.61 ± 9.59
Week 8-27.39 ± 5.97-39.59 ± 5.83-31.94 ± 11.64-31.26 ± 18.57
SecondaryAbsolute Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)

Change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) measured in millimoles per liter (mmol/L). Change from baseline = value at observation minus baseline value. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · mmol/L
Absolute Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)
mmol/LStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Baseline0.54 ± 0.150.76 ± 0.300.65 ± 0.110.99 ± 0.31
Week 2-0.22 ± 0.12-0.31 ± 0.38-0.12 ± 0.29-0.38 ± 0.33
Week 4-0.18 ± 0.24-0.30 ± 0.27-0.14 ± 0.24-0.39 ± 0.35
Week 6-0.01 ± 0.17-0.28 ± 0.32-0.20 ± 0.17-0.36 ± 0.28
Week 8-0.13 ± 0.32-0.42 ± 0.28-0.35 ± 0.14-0.55 ± 0.32
SecondaryPercent Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)

Very low-density lipoprotein-cholesterol (VLDL-C): percent (%) change from baseline by treatment over time = \[VLDL-C at observation minus VLDL-C at Week 0\] divided by VLDL-C at Week 0 \* 100. Assessments were performed in the fasting state (minimum 10-hour fast \[optional at Weeks 2 and 6\]).

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8
Reported as:
Mean · percent change in VLDL-C
Percent Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)
percent change in VLDL-CStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Week 2-42.20 ± 25.17-28.49 ± 43.50-14.50 ± 41.19-39.95 ± 37.24
Week 4-30.66 ± 48.66-31.86 ± 37.62-21.10 ± 37.56-36.35 ± 28.79
Week 64.10 ± 36.46-25.59 ± 44.90-29.20 ± 25.11-35.08 ± 25.06
Week 8-12.31 ± 57.38-50.29 ± 21.44-53.61 ± 19.21-52.38 ± 29.34
SecondaryAbsolute Change From Baseline in Flow-Mediated Dilatation at Week 8

Brachial artery flow-mediated dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. Standardized image acquisition: brachial artery images recorded for one minute at rest, blood pressure cuff inflated to 250 mm Hg for 5 minutes with brachial artery imaged continuously throughout cuff inflation, cuff released to produce reactive hyperaemia and the brachial artery imaged continuously for 3 minutes after release. Total duration of measurement approximately 25 minutes. Change from baseline = value at observation minus baseline value.

Time frame:
Baseline, Week 8
Reported as:
Mean · FMD
Absolute Change From Baseline in Flow-Mediated Dilatation at Week 8
FMDStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Baseline4.34 ± 3.157.41 ± 3.305.05 ± 3.863.67 ± 2.51
Week 8-0.16 ± 2.32-1.14 ± 1.47-0.32 ± 4.831.35 ± 2.73
SecondaryPercent Change From Baseline in Flow-Mediated Dilatation at Week 8

Brachial Flow-Mediated Dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. .

Time frame:
Baseline, Week 8
Reported as:
Mean · percent change in FMD
Percent Change From Baseline in Flow-Mediated Dilatation at Week 8
percent change in FMDStayed at 5 mg: Tanner Stage 1Titrated to 10 mg: Tanner Stage 1Stayed at 10 mg: Tanner Stage 2+Titrated to 20 mg: Tanner Stage 2+
Percent Change From Baseline in Flow-Mediated Dilatation at Week 8-17.19 ± 23.67-20.77 ± 37.03-9.77 ± 63.201.49 ± 28.64
PrimaryParent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Apparent Volume of Distribution of the Central Compartment (Vc/F)

Parent-metabolite population PK model built using sparse blood samples from Tanner Stages 1 and 2+. Sampling times: Weeks 2 + 6: single sample between 4 -12 hours postdose; Weeks 4 + 8: predose, 1 + 2 hours postdose. Plasma samples analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using validated, sensitive, specific high-performance liquid chromatography tandem mass spectrometric method. Vc/F value based on 70 kg body weight. Parameter estimation uncertainty (95% CI) by non-parametric bootstrap analysis. Data presented are result of model used.

Time frame:
Week 2, Week 4, Week 6, Week 8
Reported as:
Number · liters
Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Apparent Volume of Distribution of the Central Compartment (Vc/F)
litersAtorvastatin (5 mg, 10 mg, 20 mg): Tanner Stages 1 and 2+
Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Apparent Volume of Distribution of the Central Compartment (Vc/F)1020 (209 to 2210)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Subjects (5 mg, 10 mg): Tanner Stage 1—0/15 (0%)9/15 (60%)
All Subjects (10 mg, 20 mg): Tanner Stage 2+—0/24 (0%)13/24 (54.2%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventAll Subjects (5 mg, 10 mg): Tanner Stage 1All Subjects (10 mg, 20 mg): Tanner Stage 2+
Viral upper respiratory tract infectionInfections and infestations3/150/24
HeadacheNervous system disorders2/151/24
NasopharyngitisInfections and infestations1/152/24
Alanine aminotransferase increasedInvestigations0/152/24
Abdominal painGastrointestinal disorders1/150/24
NauseaGastrointestinal disorders1/150/24
VomitingGastrointestinal disorders1/150/24
BronchopneumoniaInfections and infestations1/150/24
Gastritis viralInfections and infestations1/150/24
GastroenteritisInfections and infestations1/151/24

Baseline characteristics

Age, Customized
Age, Customized(participants)Atorvastatin (5 mg, 10 mg): Tanner Stage 1Atorvastatin (10 mg, 20 mg): Tanner Stage 2+Total
6-8 years707
9-10 years639
11-14 years21416
15-17 years077
Sex: Female, Male
Sex: Female, Male(Participants)Atorvastatin (5 mg, 10 mg): Tanner Stage 1Atorvastatin (10 mg, 20 mg): Tanner Stage 2+Total
Female71219
Male81220
08

Study locations

3 sites
  • Pfizer Investigational Site
    Quebec, G1V 4G2, Canada
  • Pfizer Investigational Site
    Athens, 115 27, Greece
  • Pfizer Investigational Site
    Oslo, 0027, Norway
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2008
First posted
Aug 22, 2008
Start
Dec 2008
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Aug 20, 2010
Last update
Mar 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00739999
Responsible party
Sponsor
First posted
Aug 22, 2008
Start date
Dec 2008
Primary completion
May 2009
Completion
May 2009
Results posted
Aug 20, 2010
Last update
Mar 15, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion